The tell-tale heart: Molecular and cellular responses to childhood anthracycline exposure

Merry L. Lindsey, Richard A. Lange, Helen Parsons, Thomas Andrews, Gregory J. Aune

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Since the modern era of cancer chemotherapy that began in the mid-1940s, survival rates for children afflicted with cancer have steadily improved from 10% to current rates that approach 80% (60). Unfortunately, many long-term survivors of pediatric cancer develop chemotherapy-related health effects; 25% are afflicted with a severe or life-threatening medical condition, with cardiovascular disease being a primary risk (96). Childhood cancer survivors have markedly elevated incidences of stroke, congestive heart failure (CHF), coronary artery disease, and valvular disease (96). Their cardiac mortality is 8.2 times higher than expected (93). Anthracyclines are a key component of most curative chemotherapeutic regimens used in pediatric cancer, and approximately half of all childhood cancer patients are exposed to them (78). Numerous epidemiologic and observational studies have linked childhood anthracycline exposure to an increased risk of developing cardiomyopathy and CHF, often decades after treatment. The acute toxic effects of anthracyclines on cardiomyocytes are well described; however, myocardial tissue is comprised of additional resident cell types, and events occurring in the cardiomyocyte do not fully explain the pathological processes leading to late cardiomyopathy and CHF. This review will summarize the current literature regarding the cellular and molecular responses to anthracyclines, with an important emphasis on nonmyocyte cardiac cell types as well as those that mediate the myocardial injury response.

Original languageEnglish (US)
Pages (from-to)H1379-H1389
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume307
Issue number10
DOIs
StatePublished - Nov 15 2014

Fingerprint

Anthracyclines
Neoplasms
Heart Failure
Cardiomyopathies
Cardiac Myocytes
Survivors
Pediatrics
Drug Therapy
Poisons
Pathologic Processes
Observational Studies
Epidemiologic Studies
Coronary Artery Disease
Cardiovascular Diseases
Survival Rate
Stroke
Mortality
Incidence
Health
Wounds and Injuries

Keywords

  • Anthracyclines
  • Cardiomyocytes
  • Cardiomyopathy
  • Congestive heart failure
  • Extracellular matrix
  • Fibroblast

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

The tell-tale heart : Molecular and cellular responses to childhood anthracycline exposure. / Lindsey, Merry L.; Lange, Richard A.; Parsons, Helen; Andrews, Thomas; Aune, Gregory J.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 307, No. 10, 15.11.2014, p. H1379-H1389.

Research output: Contribution to journalReview article

Lindsey, Merry L. ; Lange, Richard A. ; Parsons, Helen ; Andrews, Thomas ; Aune, Gregory J. / The tell-tale heart : Molecular and cellular responses to childhood anthracycline exposure. In: American Journal of Physiology - Heart and Circulatory Physiology. 2014 ; Vol. 307, No. 10. pp. H1379-H1389.
@article{f4012676b0b94339a7d14f7d8a2b38b8,
title = "The tell-tale heart: Molecular and cellular responses to childhood anthracycline exposure",
abstract = "Since the modern era of cancer chemotherapy that began in the mid-1940s, survival rates for children afflicted with cancer have steadily improved from 10{\%} to current rates that approach 80{\%} (60). Unfortunately, many long-term survivors of pediatric cancer develop chemotherapy-related health effects; 25{\%} are afflicted with a severe or life-threatening medical condition, with cardiovascular disease being a primary risk (96). Childhood cancer survivors have markedly elevated incidences of stroke, congestive heart failure (CHF), coronary artery disease, and valvular disease (96). Their cardiac mortality is 8.2 times higher than expected (93). Anthracyclines are a key component of most curative chemotherapeutic regimens used in pediatric cancer, and approximately half of all childhood cancer patients are exposed to them (78). Numerous epidemiologic and observational studies have linked childhood anthracycline exposure to an increased risk of developing cardiomyopathy and CHF, often decades after treatment. The acute toxic effects of anthracyclines on cardiomyocytes are well described; however, myocardial tissue is comprised of additional resident cell types, and events occurring in the cardiomyocyte do not fully explain the pathological processes leading to late cardiomyopathy and CHF. This review will summarize the current literature regarding the cellular and molecular responses to anthracyclines, with an important emphasis on nonmyocyte cardiac cell types as well as those that mediate the myocardial injury response.",
keywords = "Anthracyclines, Cardiomyocytes, Cardiomyopathy, Congestive heart failure, Extracellular matrix, Fibroblast",
author = "Lindsey, {Merry L.} and Lange, {Richard A.} and Helen Parsons and Thomas Andrews and Aune, {Gregory J.}",
year = "2014",
month = "11",
day = "15",
doi = "10.1152/ajpheart.00099.2014",
language = "English (US)",
volume = "307",
pages = "H1379--H1389",
journal = "American Journal of Physiology - Renal Physiology",
issn = "0363-6127",
publisher = "American Physiological Society",
number = "10",

}

TY - JOUR

T1 - The tell-tale heart

T2 - Molecular and cellular responses to childhood anthracycline exposure

AU - Lindsey, Merry L.

AU - Lange, Richard A.

AU - Parsons, Helen

AU - Andrews, Thomas

AU - Aune, Gregory J.

PY - 2014/11/15

Y1 - 2014/11/15

N2 - Since the modern era of cancer chemotherapy that began in the mid-1940s, survival rates for children afflicted with cancer have steadily improved from 10% to current rates that approach 80% (60). Unfortunately, many long-term survivors of pediatric cancer develop chemotherapy-related health effects; 25% are afflicted with a severe or life-threatening medical condition, with cardiovascular disease being a primary risk (96). Childhood cancer survivors have markedly elevated incidences of stroke, congestive heart failure (CHF), coronary artery disease, and valvular disease (96). Their cardiac mortality is 8.2 times higher than expected (93). Anthracyclines are a key component of most curative chemotherapeutic regimens used in pediatric cancer, and approximately half of all childhood cancer patients are exposed to them (78). Numerous epidemiologic and observational studies have linked childhood anthracycline exposure to an increased risk of developing cardiomyopathy and CHF, often decades after treatment. The acute toxic effects of anthracyclines on cardiomyocytes are well described; however, myocardial tissue is comprised of additional resident cell types, and events occurring in the cardiomyocyte do not fully explain the pathological processes leading to late cardiomyopathy and CHF. This review will summarize the current literature regarding the cellular and molecular responses to anthracyclines, with an important emphasis on nonmyocyte cardiac cell types as well as those that mediate the myocardial injury response.

AB - Since the modern era of cancer chemotherapy that began in the mid-1940s, survival rates for children afflicted with cancer have steadily improved from 10% to current rates that approach 80% (60). Unfortunately, many long-term survivors of pediatric cancer develop chemotherapy-related health effects; 25% are afflicted with a severe or life-threatening medical condition, with cardiovascular disease being a primary risk (96). Childhood cancer survivors have markedly elevated incidences of stroke, congestive heart failure (CHF), coronary artery disease, and valvular disease (96). Their cardiac mortality is 8.2 times higher than expected (93). Anthracyclines are a key component of most curative chemotherapeutic regimens used in pediatric cancer, and approximately half of all childhood cancer patients are exposed to them (78). Numerous epidemiologic and observational studies have linked childhood anthracycline exposure to an increased risk of developing cardiomyopathy and CHF, often decades after treatment. The acute toxic effects of anthracyclines on cardiomyocytes are well described; however, myocardial tissue is comprised of additional resident cell types, and events occurring in the cardiomyocyte do not fully explain the pathological processes leading to late cardiomyopathy and CHF. This review will summarize the current literature regarding the cellular and molecular responses to anthracyclines, with an important emphasis on nonmyocyte cardiac cell types as well as those that mediate the myocardial injury response.

KW - Anthracyclines

KW - Cardiomyocytes

KW - Cardiomyopathy

KW - Congestive heart failure

KW - Extracellular matrix

KW - Fibroblast

UR - http://www.scopus.com/inward/record.url?scp=84925068592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925068592&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00099.2014

DO - 10.1152/ajpheart.00099.2014

M3 - Review article

C2 - 25217655

AN - SCOPUS:84925068592

VL - 307

SP - H1379-H1389

JO - American Journal of Physiology - Renal Physiology

JF - American Journal of Physiology - Renal Physiology

SN - 0363-6127

IS - 10

ER -